key: cord-0700591-yfmgdwtq
authors: Falcone, Marco; Suardi, Lorenzo Roberto; Tiseo, Giusy; Barbieri, Chiara; Giusti, Lisa; Galfo, Valentina; Forniti, Arianna; Caroselli, Claudio; Sala, Leonardo Della; Tempini, Sara; Okoye, Chukwuma; Monzani, Fabio; Menichetti, Francesco
title: Early use of remdesivir and risk of disease progression in hospitalized patients with mild-to moderate COVID-19
date: 2022-01-17
journal: Clin Ther
DOI: 10.1016/j.clinthera.2022.01.007
sha: 5f6a91d8710eea9bcc8542517f88d5d506cea0b9
doc_id: 700591
cord_uid: yfmgdwtq

Purpose Preliminary data suggest that remdesivir may influence the course of COVID-19 according to the duration of pre-admission symptoms. We aim to evaluate whether an early use of remdesivir is associated with a reduced COVID-19 progression in a homogeneous cohort of patients with mild-to-moderate COVID-19. Methods This prospective observational study included patients withCOVID-19 pneumonia treated with remdesivir at the University Hospital of Pisa (Italy) fromSeptember 2020 to January 2021. According to the national recommendations remdesivir was prescribed in patients with pneumonia who required oxygen supplementation by nasal cannula or mask but without the need for high-flow nasal cannula (HFNC),non-invasiveventilation (NIV) or invasive mechanical ventilation (MV) and had symptoms from no more than 10 days. Patients who received early (<5 days from onset of symptoms) and late (>5 days from onset of symptoms) remdesivir were compared. The primary outcome was a composite of HFNC, NIV, invasiveMV or death. A multivariate logistic regression analysis was performed to identify factors independently associated with the composite endpoint. Findings Among 312 consecutive patients with COVID-19 pneumonia who received remdesivir, 90 (28.8%) patients received early remdesivir, while 222 (71.2%) late remdesivir. Twenty-nine (32.2%) patients in the early-remdesivir group versus 104 (46.8%) patients in the late-remdesivir group met the primary endpoint (p=0.018). On multivariate analysis, a history of dyspnea at home (OR 2.53, 95% CI 1.55-4.12, p<0.001) was the strongest factor independently associated with the progression to severe COVID-19, while early-remdesivir use was a protective factor (OR 0.49, 95% CI 0.27-0.87, p=0.015). The delayed admission to the hospital was associated with a delayed administration of remdesivir. Implications The early use of remdesivir (<5 days from symptoms onset) may reduce the COVID-19 progression. The identification of patients who need early hospitalization and early remdesivir may provide clinical benefit in patients with COVID-19.

The treatment options for patients with COVID-19 have dramatically changed since thebeginning of the pandemic and the management of patients needing hospitalization is still being studied [1] .

Immunomodulatory therapy withmonoclonal antibodies [2] , corticosteroids [3] , tocilizumab [4] and baricitinib [5] demonstrated to reduce mortality in RECOVERY trial in the so-called "hyperinflammatory" phase of infection. Conversely, during the initial phase of infection, where viral replication predominates, the only antiviral drug approved for clinical use is remdesivir.

Remdesivir has been approved by the Italian Medicines Agency (AIFA) for the treatment of hospitalized patients requiring supplemental oxygenwithin 10 days since symptoms onset [6] .

Patientswho need high-flow nasal cannula (HFNC) or non-invasive ventilation (NIV) or invasive mechanical ventilation (MV) or extracorporeal membrane oxygenation (ECMO) are excluded [6] .

This restriction to remdesivir use is based on the results of published randomized clinical trials [7] [8] [9] .

However, while it is known that remdesivir decreases the duration of symptoms, it is still questionable if remdesivir reduces the mortality of patientsinfected with COVID-19. As a matter of fact, the SOLIDARITY trial did not demonstrate a reduction of mortality of patients treated with remdesivir [8] . Instead, the ACTT-1 trial showed a significant benefit of remdesivir therapy compared to placebo on clinical recovery andmortality in the subgroup of patients requiring lowflow oxygen therapy [9] . These controversial results could be explained by the different timing of administration of this antiviral and need to be more investigated.

The aim of this study was to evaluate whether the early treatment with remdesivir compared to the delayed use is associated or not with improved clinical outcome.

This prospective observational study includedpatients withSARS-CoV2 infection confirmed by real-time reverse-transcription polymerase chain reaction (rRT-PCR) on nasopharyngeal throat swabs admitted to the University Hospital of Pisa (Italy) during the second wave of the COVID-19 pandemic (September 2020-January 2021) who received remdesivir. All patients received the same standard of care treatment according to national and local guidelines [5] [6] 10] . In our hospital, a panel of experts elaborated a guide for the management of COVID-19 patients, which was regularly updated according to any new release from scientific literature (Supplementary Table 1 ). Patients were prospectively followed-up until discharge or death.Data concerning demographics (age, sex), comorbidities, history of COVID-19 symptoms at home, clinical presentation and laboratory findings on admission at the Emergency Department (ED), COVID-19 treatment and outcome were prospectively collected. Non-invasive/invasive-ventilatory support (NI/I-VS) was defined as the need for HFNC, NIV or invasive MV. The study wasconducted according to the principles stated in the Declarationof Helsinki. The local ethics committee approved the study.

The primary objective of the study was to evaluate the impactof the early treatment with remdesivir (exposure variable) in preventing the progression to severe COVID-19 pneumonia. In particular, the research question was toevaluate whether early compared to late treatment with remdesivir is effective in reducing the risk of progression to severe COVID-19, defined as a composite of need of HFNC or NIV or invasiveMV or death (main outcome measure).

Intravenous remdesivir was administered (200mg on the first day and 100mg once daily from day 2 to day 5), according to the AIFA criteria. Inclusion criteria included radiological confirmed pneumonia, symptoms onset within 10 days, need of supplemental low-flow oxygen. Exclusion criteria were requirement of HFNV, MV, vasoactive drugs, ECMO. Contraindications included aspartate amino transferase (AST) and alanine amino transferase (ALT) ≥5 times the normal range values, glomerular filtration < 30 m/min. Patients receiving early treatment with remdesivir were defined as those who had initiated remdesivir intravenously within the first 5 days from the onset of symptoms. Treatment exposure period was calculatedfrom symptoms onset (and not from hospital admission) to mitigateselection bias due to heterogeneity of treatment initiation daysbetween patients. Patients who had initiated remdesivir after 5 days from symptoms onsetwere included in the control group (late remdesivir group).

According to the study outcome, a comparison between patients who met the primary endpoint and those who did not was performed. Patients who did not receive remdesivir (according to exclusion criteria), those who received do not resuscitate order (DNR) and subjects who died within the first 24 hours from hospital admission were excluded from the analysis.

Continuous variables are reported as mean ± standard deviation and medians and interquartile ranges (IQRs) according totheir distribution. The normality of distributions was assessedby the Kolmogorov-Smirnov test. Continuous variables werecompared by the Student t test or the Mann-Whitney U test, asappropriate. Categorical data were expressed as frequency distributions, and the χ2 test or Fisher exact test was used to determine whether differences existed between groups.

A multivariate analysis to identify factors independently associated with the primary endpoint was performed. Multivariate analysis using logistic regression predictionmodels was constructed using a forward stepwise procedure, entering all variables with univariate p < 0.05 andthose deemed clinically significant.The finalmultivariate model was chosen according to the Akaike informationcriterion, and to parsimony and clinical interpretabilityof data. The odds ratio (OR) with 95% confidence intervals (95% CI) were calculated. Kaplan Meier curves were built to compare timeto disease progression between patients in the early-remdesivir group versus those in the lateremdesivir group. Nonparametric (log-rank) tests were usedto compare event-free survival functions in the 2 study groups. A subgroup analysis was also carriedout to evaluate differences in the primary endpoint in patients admitted to the hospital within 5 days from onset of symptoms.

A value of p < 0.05 was considered statistically significant. The statistical analysis was conducted using IBM SPSS Statistics version 23.0 software (IBM Corp., Armonk, NY, USA).

A total of 312 consecutive patients with COVID-19 pneumonia who received remdesivir were included in the study. Median age was 69 (IQRs 58-81) years. A total of 142 patients (45.5%) were admitted to the hospital within 5 days from onset of symptoms. Ninety (28.8%) patients received remdesivir within <5 days while 222 (71.2%) after 5 days fromsymptoms onset. Patients who received early remdesivir were older, more frequently affected by chronic pulmonary disease, chronic heart disease and cerebrovascular disease ( Table 1) . Conversely, patients who received remdesivir after 5 days from onset of symptoms had more frequently history of fever and cough at home ( Table 1) . The 2 study groups were comparable in term of concomitant treatments for COVID-19: the whole population received intravenous corticosteroid therapy (dexamethasone 6 mg per day) and prophylactic dose of low-molecular weight heparin.

Twenty-nine (32.2%) patients in the early-remdesivir group versus 104 (46.8%) patients in the lateremdesivir group had a progression to severe COVID-19 (p=0.018). Comparison of patients who met the primary endpoint and those who did not is shown in Table 2 . Compared to patients who had not progression to severe COVID-19, those who met the primary endpoint had more frequently history of fever and dyspnea before ED admission, a PiO2/FiO2 ratio < 300 and CRP > 5 mg/dl at ED admission. With regards to therapies, patients who had no disease progression were more commonly treated with early-remdesivir. On multivariate analysis, history of dyspnea before ED admission (OR 2.53, 95% CI 1.55-4.12, p<0.001), a PiO2/FiO2 ratio < 300 (OR 2.22, 95% CI 1.35-3.63, p=0.002), C-reactive protein > 5 mg/dl at admission (OR 1.66, 95% CI 1.01-2.72, p=0.044) and age (OR 1.02, 95% CI 1.003-1.04, p=0.025) were factors independently associated with the progression to severe COVID-19, while early-remdesivir administration was the only protective factor (OR 0.49, 95% CI 0.27-0.87, p=0.015) ( Table 3) . Kaplan-Meier survival curvesshowed a statistically significant beneficial effect of early-remdesivir compared to late-remdesivir treatment on COVID-19 progression-free survival (Figure 1) .

Factors associated with a delayed hospital admission are reported in Supplementary Table 2 .

Compared to patients admitted to the hospital after 5 days from symptom onset, patients who were admitted within 5 days were older, were more frequently resident in a long-term care facility, and were more commonly affected by chronic heart disease. Conversely, those admitted later with respect to the onset of symptoms had more frequently fever and cough before hospital admission and parameters of inflammations (increased C-reactive protein and elevated D-dimer value) at ED admission. Patients admitted within the first 5 days from hospital admission received more frequently early remdesivir treatment (p<0.001).

The subgroup analysis showed that, among 142 patients admitted to the hospital within 5 days from onset of symptoms, the progression to severe COVID-19 occurred in 29/90 (32.2%) patients who received early remdesivir compared to 24/52 (46.2%) patients who received late remdesivir (p=0.098) (SupplementaryTable 3). Comparison of patients who had or not disease progression is showed in Table 4 . The time from symptoms onset to the start of remdesivir was longer in patients who had disease progression compared to those who did not (5 [IQRs 3-7] versus 4 [IQRs 2 -6] days, p=0.007).

We demonstrated that the early treatment with remdesivir (within the first 5 days from onset of symptoms) is associated with lower risk of progression to severe disease in hospitalized patients with COVID-19 pneumonia. Notably, in our study population the concomitant treatments for COVID-19 were well standardized and all patients received the same concomitant therapies, supporting the robustness of our observations.Our main finding was that history of dyspnea at home was the factor more strongly associated with poor outcome, while remdesivir within the first 5 days from onset of symptoms was associated with a 51% of reduction of disease progression.

Our study suggests 2 important observations. First, the identification of COVID-19 patients who can benefit from an early admission to the hospital has a pivotal importance and a delayed decision to hospitalize patients at high risk of progression might preclude them from the opportunity to receive potentially life-saving treatments. We highlighted that patients admitted within the first 5 days from onset of symptoms were older, became more commonly from long-term care facilities and had more frequently heart disease compared to patients who were admitted later. These findings underline the awarenessof territorial physicians on age, comorbidities and frailty of the patients.

However, other factors, such as the presence of fever and cough at home and the presence of an inflammatory status, were underestimated and associated with a delayed decision to hospitalize the patients. The delayed hospitalization was obviously associated with a late use of remdesivir and, ultimately, to an increased probabilityof disease progression.

Second, the published RCTs on remdesivir did not provide exhaustive and concordant evidence about the efficacy of the antiviral in all patients with COVID-19 [7] [8] [9] [12] [13] . A great heterogeneity among the different studies, different timing of remdesivir administration according to the onset of symptoms may have partially explain this discrepancy. Conversely, data from the real-life seem to support our observation. As a matter of fact, our study is in line with a recent study that evaluate the impact of remdesivir according to the pre-admission symptomduration in patients with COVID-19 [11] . In this study, Garcia Vidal and collaborators showed that patients with <= 3 days and 4-6 days from symptom onset to admission had a 2.5-and 1.5-fold higher risk of death, respectively [11] . Moreover, remdesivir was associated with 62% reduced odds of death versus standard-of-care: this benefit was observed in patients who were admitted within the first 6 days but not in those admitted later to the hospital [11] . A recent study comparing 28.855 patients who received remdesivir to matched subjects who did not, showed that within 2 days from hospitalization showed that remdesivir was associated with a reduction in mortality at 14 days and 28 days [14] . This benefit was confirmed also in special categories, such as patients who underwent MV and ECMO [14] . In line with this study, our findings provide further support that early start of remdesivir may be an foundational treatment approach for COVID-19.

A phase 3 randomized clinical trial evaluating the role of remdesivir in an outpatient setting has been recently completed and preliminary results showed that remdesivir reduced risk of hospitalizations by 87% compared with placebo in this category of patients [15] .

Similarly, a recent territory-wide retrospective study showed that early treatment with remdesivir was associated with a lower risk of in-hospital death [16] . The authors demonstrated that that early initiation of 5-day remdesivir treatment within two days of admissionwas associated with significantly shorter time to clinical improvement, low viral load andpositive IgG antibody, a shorter hospital LOS, and a lower risk of in-hospital death comparedto not using the antiviral drug [16] . Their suggestion is to extend the use of remdesivir to patients presenting with moderate disease but not requiring oxygen therapy on admission [16] . In this study treatment exposure periodwas set at 2 days from hospital admission. Conversely, we defined the early treatment with remdesivir as the receipt of remdesivir within 5 days from symptoms onset. This time point may be more appropriate for the following reasons: 1) the choice of start of symptoms as the "day 0" may ensure more homogeneity among patients; 2) it may better reflect the initial phase of infection, where viral replication predominates; 3) the use of remdesivir within 5 days from symptoms onset may be quite feasible in the clinical practice.

Our study has some limitations. First, the sample size is relatively small. However, the study population is homogeneous because all patients had the same criteria to receive remdesivir and were treated with the same standard of care defined at national level and applied in our hospital. Second, data about the serological status and the viral load before the start of remdesivir are lacking, but may provide important information about the phase of the COVID-19 disease. Third, as for the observational nature of the study, the two groups of patients who received early and late remdesivir differ in term of age and baseline comorbidities. However, since patients in the "early remdesivir" group were older and had more comorbidities, you can expect that these patientshad a high risk of progression to severe COVID-19. Anyway, to overcome this potential selection bias we performed a multivariate analysis considering all factors that potentially influence patients' outcome and a subgroup analysis evaluating the role of early remdesivir in the subgroup of patients admitted to the hospital within 5 days from onset of symptoms. In conclusion, in our study remdesivir was useful to The multivariate model was performed using a forward stepwise procedure. Variables entered to the regression but not retained were: age, Chronic pulmonary disease, Hypertension, Temperature > 37.5 and dyspnea before hospital admission, P/F ratio < 300 on admission C-reactive protein > 5 mg/dl (variables with statistical significance at the univariate comparison reported in Table 2 ). 

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)

efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe covid-19 and role of variants of concern

Dexamethasone in Hospitalized Patients with Covid-19

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

Medicines usable for treatment of COVID-19 disease. Remdesivirin the treatmentof adult patientswith COVID-19

Last accessed on: 26 th

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

Repurposed antiviral drugs for covid-19 -interim who Solidarity trial results

ACTT-1 study group members. remdesivir for the treatment of covid-19 -final report

Role of low-molecular-weight heparin in hospitalized patients with severe acute respiratory syndrome coronavirus 2 pneumonia: a prospective observationalstudy

Impact of remdesivir according to the preadmission symptom duration in patients with COVID-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

ACTT-2 study group members. baricitinib plus remdesivir for hospitalized adults with Covid-19

Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with COVID-19

We thank the participants of the study.

We received an unconditional support from Gilead Sciences to collect and analysis data.

(ICMJE) criteria for authorship for thisarticle, take responsibility for the integrity ofthe work as a whole, and have given theirapproval for this version to be published